# Open Label Study of Adalimumab in Subjects Who Have a Sub-optimal Response to Systemic Therapy or Phototherapy

> **NCT00566722** · PHASE3 · COMPLETED · sponsor: **Abbott** · enrollment: 152 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **BIOLOGICAL:** adalimumab

## Key facts

- **NCT ID:** NCT00566722
- **Lead sponsor:** Abbott
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2009-04
- **Final completion:** 2009-04
- **Target enrollment:** 152 (ACTUAL)
- **Last updated:** 2011-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00566722

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00566722, "Open Label Study of Adalimumab in Subjects Who Have a Sub-optimal Response to Systemic Therapy or Phototherapy". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00566722. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*